Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• HallPESpicerJPopatSRationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lungFuture Oncol201511152175219126039665
   PubMed Web of Science ®Google Scholar
• GoldKAWistubaIIKimESNew strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapyClin Cancer Res201218113002300722461458
   PubMed Web of Science ®Google Scholar
• ArriagadaRBergmanBDunantALe ChevalierTPignonJPVansteenkisteJCisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancerN Engl J Med2004350435136014736927
   PubMed Web of Science ®Google Scholar
• RoengvoraphojMTsongalisGJDragnevKHRigasJREpidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patientsCancer Treat Rev201339883985023768755
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• NormandoSRCruzFMDel GiglioACumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancerAnticancer Drugs2015269995100326237501
   PubMed Web of Science ®Google Scholar
• JohnsonDHFehrenbacherLNovotnyWFRandomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol200422112184219115169807
   PubMed Web of Science ®Google Scholar
• HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543355118506025
   PubMed Web of Science ®Google Scholar
• YapTAVidalLAdamJPhase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsJ Clin Oncol201028253965397220679611
   PubMed Web of Science ®Google Scholar
• YangJCShihJYSuWCAfatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialLancet Oncol201213553954822452895
   PubMed Web of Science ®Google Scholar
• MachielsJPHaddadRIFayetteJAfatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialLancet Oncol201516558359425892145
   PubMed Web of Science ®Google Scholar
• O’ConnorKFDA approves GILOTRIF™ (afatinib) as first-line treatment for metastatic non-small cell lung cancer with common EGFR mutations2013 Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2013/07-12-13-fda-approves-gilotrif-afatinib-first-line-treatment-metastatic-non-small-cell-lung-cancer-common-egfr-mutations.htmlAccessed May 17, 2016
   Google Scholar
• DungoRTKeatingGMAfatinib: first global approvalDrugs201373131503151523982599
   PubMed Web of Science ®Google Scholar
• SolcaFDahlGZoephelATarget binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blockerJ Pharmacol Exp Ther2012343234235022888144
   PubMed Web of Science ®Google Scholar
• MeloskyBReview of EGFR TKIs in metastatic NSCLC, including ongoing trialsFront Oncol2014424425309870
   PubMedGoogle Scholar
• ModjtahediHChoBCMichelMCSolcaFA comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancerNaunyn Schmiedebergs Arch Pharmacol2014387650552124643470
   PubMed Web of Science ®Google Scholar
• HynesNELaneHAERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer20055534135415864276
   PubMed Web of Science ®Google Scholar
• GazdarAFEpidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapyCancer Metastasis Rev2010291374820127143
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• ChenXZhuQZhuLClinical perspective of afatinib in non-small cell lung cancerLung Cancer201381215516123664448
   PubMed Web of Science ®Google Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
• YapTAPopatSToward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancerPharmacogenomics Pers Med20147285295
   PubMedGoogle Scholar
• HirshVCadranelJCongXJSymptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1)J Thorac Oncol20138222923723328549
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuC-PLUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lungPaper presented at: ASCO Annual Meeting ProceedingsMay 31–June 4, 2013Chicago, IL
   Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• YangJC-HSequistLVSchulerMHOverall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT)Paper presented at: ASCO Annual Meeting ProceedingsMay 30–June 4, 2014Chicago, IL
   Google Scholar
• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• KatakamiNAtagiSGotoKLUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or bothJ Clin Oncol201331273335334123816963
   PubMed Web of Science ®Google Scholar
• SchulerMHYangC-HParkKContinuation of afatinib beyond progression: results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib – LUX-Lung 5 (LL5)Paper presented at: ASCO Annual Meeting ProceedingsMay 30–June 4, 2014Chicago, IL
   Google Scholar
• HeinmollerPGrossCBeyserKHER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptinClin Cancer Res20039145238524314614004
   PubMed Web of Science ®Google Scholar
• PassaroAPochesciASpitaleriGAfatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?J Thorac Dis201683E217E22027076973
   PubMed Web of Science ®Google Scholar
• ParkKTanEHO’ByrneKAfatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialLancet Oncol2016175577589
   PubMed Web of Science ®Google Scholar
• KimJ-HGrossiFDe MarinisFAfatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: interim subset analysis from a phase III trialJ Clin Oncol201230Suppl abstr 7558
   Google Scholar
• ParkKKimJSchulerMAfatinib (A) followed by A+ paclitaxel (P) or investigator’s choice of single-agent chemotherapy (IC) in patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: subgroup analysis of LUX-Lung 5 (LL5)Ann Oncol201425Suppl 4iv443iv444
   Google Scholar
• GossGFelipECoboMA randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8)Ann Oncol201425Suppl 4iv426
   Google Scholar
• SoriaJCFelipECoboMAfatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialLancet Oncol201516889790726156651
   PubMed Web of Science ®Google Scholar
• boehringer-ingelheim.com [homepage on the Internet]FDA approves Gilotrif^® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung2016 Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2016/4-15-2016-fda-approves-gilotrif-afatinib-oral-treatment-option-patients-squamous-cell-carcinoma-lung.htmlAccessed April 15, 2016
   Google Scholar
• Lo RussoGProtoCGarassinoMCAfatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?Transl Lung Cancer Res20165111011426958504
   PubMed Web of Science ®Google Scholar
• DeardenSStevensJWuYLBlowersDMutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)Ann Oncol20132492371237623723294
   PubMed Web of Science ®Google Scholar
• HirschFRVarella-GarciaMBunnPAEpidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosisJ Clin Oncol200321203798380712953099
   PubMed Web of Science ®Google Scholar
• CappuzzoFHirschFRRossiEEpidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancerJ Natl Cancer Inst200597964365515870435
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• De GreveJMoranTGraasMPPhase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinomaLung Cancer2015881636925682316
   PubMed Web of Science ®Google Scholar
• CappuzzoFFinocchiaroGGrossiFPhase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancerJ Thorac Oncol201510466567225514804
   PubMed Web of Science ®Google Scholar
• HirschFRFranklinWAVeveRVarella-GarciaMBunnPAJrHER2/neu expression in malignant lung tumorsSemin Oncol2002291 Suppl 4515811894014
   PubMed Web of Science ®Google Scholar
• UgocsaiKMandokyLTiszlaviczLMolnarJInvestigation of HER2 overexpression in non-small cell lung cancerAnticancer Res20052543061306616080566
   PubMed Web of Science ®Google Scholar
• YiESHarclerodeDGondoMHigh c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomasMod Pathol19971021421489127320
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive genomic characterization of squamous cell lung cancersNature2012489741751952522960745
   PubMed Web of Science ®Google Scholar
• NelsonVZiehrJAgulnikMJohnsonMAfatinib: emerging next-generation tyrosine kinase inhibitor for NSCLCOncotargets Ther20136135143
   PubMed Web of Science ®Google Scholar
• ChaoTTWangCYChenYLAfatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2AOncotarget2015642164217925537503
   PubMedGoogle Scholar
• DongQZWangYDongXJCIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosisAnn Surg Oncol201118385786520842459
   PubMed Web of Science ®Google Scholar
• XuPXuXLHuangQZhangZHZhangYBCIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosisMed Oncol20122931643164721874565
   PubMed Web of Science ®Google Scholar
• D’ArcangeloMHirschFRClinical and comparative utility of afatinib in non-small cell lung cancerBiol Targets Ther20148183192
   PubMedGoogle Scholar
• GiordanoPManzoAMontaninoAAfatinib: an overview of its clinical development in non-small-cell lung cancer and other tumorsCrit Rev Oncol Hematol20169714315126318094
   PubMed Web of Science ®Google Scholar
• ReckMPopatSReinmuthNDe RuysscherDKerrKMPetersSMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii27iii3925115305
   PubMed Web of Science ®Google Scholar
• GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
   PubMed Web of Science ®Google Scholar
• RizviNAMazieresJPlanchardDActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncol201516325726525704439
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• ThatcherNHirschFRLuftAVNecitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialLancet Oncol201516776377426045340
   PubMed Web of Science ®Google Scholar
• DermanBAMilehamKFBonomiPDBatusMFidlerMJTreatment of advanced squamous cell carcinoma of the lung: a reviewTransl Lung Cancer Res20154552453226629421
   PubMed Web of Science ®Google Scholar
• GandaraDRHammermanPSSosMLLaraPNHirschFRSquamous cell lung cancer: from tumor genomics to cancer therapeuticsClin Cancer Res201521102236224325979930
   PubMed Web of Science ®Google Scholar
• HerbstRSGandaraDRHirschFRLung Master Protocol (Lung-MAP) – a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400Clin Cancer Res20152171514152425680375
   PubMed Web of Science ®Google Scholar
• FerrarottoRRedmanMWGandaraDRHerbstRSPapadimitrakopoulouVALung-MAP – framework, overview, and design principlesChin Clin Oncol2015433626408303
   PubMedGoogle Scholar
• ClinicalTrials.gov [homepage on the Internet]US National Institutes of Health search results Available from: https://clinicaltrials.gov/ct2/results?term=Afatinib+squamous+cell+lung&Search=SearchAccessed December 25, 2015
   Google Scholar